Rilpivirine

Last Updated: 02/24/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 1671 publications

Letter to the editor: Addressing the blind spot of self-reported adherence in the era of long-acting PrEP.

Letter to the editor: Addressing the blind spot of self-reported adherence in the era of long-acting PrEP.

Journal: Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin

Published: January 16, 2026

Authors' response: Addressing the blind spot of self-reported adherence in the era of long-acting PrEP.

Authors' response: Addressing the blind spot of self-reported adherence in the era of long-acting PrEP.

Journal: Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin

Published: January 16, 2026

Cyclization-Inspired Structural Optimization: Designing Potent Non-nucleoside Reverse Transcriptase Inhibitors with Enhanced Safety and Selectivity.

Cyclization-Inspired Structural Optimization: Designing Potent Non-nucleoside Reverse Transcriptase Inhibitors with Enhanced Safety and Selectivity.

Journal: Journal of medicinal chemistry

Published: January 09, 2026

Evaluating long-acting injectable HIV treatment: an update on cabotegravir and rilpivirine.

Evaluating long-acting injectable HIV treatment: an update on cabotegravir and rilpivirine.

Journal: Expert review of anti-infective therapy

Published: January 08, 2026

Subscription-Based Pricing for Lenacapavir-Learning From Hepatitis C and Cabotegravir.

Subscription-Based Pricing for Lenacapavir-Learning From Hepatitis C and Cabotegravir.

Journal: JAMA

Published: January 07, 2026

Research trends and hotspots in HIV pre-exposure prophylaxis: a bibliometric analysis and visual mapping.

Research trends and hotspots in HIV pre-exposure prophylaxis: a bibliometric analysis and visual mapping.

Journal: AIDS reviews

Published: December 09, 2025

Cabotegravir injectable PrEP approved in England and Wales.

Cabotegravir injectable PrEP approved in England and Wales.

Journal: The lancet. HIV

Published: December 07, 2025

Bimonthly Administered Long-Acting Cabotegravir and Rilpivirine Are Highly Effective and Well-Tolerated in People With Human Immunodeficiency Virus Above 65 Years.

Bimonthly Administered Long-Acting Cabotegravir and Rilpivirine Are Highly Effective and Well-Tolerated in People With Human Immunodeficiency Virus Above 65 Years.

Journal: Open forum infectious diseases

Published: December 06, 2025

Preexposure Prophylaxis Prescription Dispensation Status and HIV-1 Acquisition.

Preexposure Prophylaxis Prescription Dispensation Status and HIV-1 Acquisition.

Journal: JAMA network open

Published: December 04, 2025

To err is human, to persist is diabolical: Are we repeating the same cost and insurance coverage mistakes again with injectable PrEP?

To err is human, to persist is diabolical: Are we repeating the same cost and insurance coverage mistakes again with injectable PrEP?

Journal: Journal of acquired immune deficiency syndromes (1999)

Published: December 02, 2025

Canadian guideline on HIV pre- and postexposure prophylaxis: 2025 update.

Canadian guideline on HIV pre- and postexposure prophylaxis: 2025 update.

Journal: CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne

Published: December 01, 2025

Impact of Gluteal Injection Site on Pharmacokinetics and Tolerability of Antiretroviral Therapy with Long-Acting Cabotegravir and Rilpivirine.

Impact of Gluteal Injection Site on Pharmacokinetics and Tolerability of Antiretroviral Therapy with Long-Acting Cabotegravir and Rilpivirine.

Journal: AIDS patient care and STDs

Published: November 17, 2025

Showing 1-12 of 1,671

Last Updated: 02/24/2026